Different influenza vaccine formulations and adjuvants for childhood influenza vaccination

Susanna Esposito, Nicola Principi

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Pediatric influenza is a very common disease: attack rates range from 23% to 48% during interpandemic years and are significantly higher during pandemics. Influenza-related complications seem to be more common in children at risk because of an underlying chronic severe disease, but recently collected data clearly demonstrate that otherwise healthy children can also suffer from severe influenza and that the annual number of deaths is no different between the two groups. The aim of this review is to discuss the characteristics of all influenza vaccines in order to evaluate the real likelihood of prevention, as well as the safety and tolerability of the different formulations and adjuvants. The data indicate that further studies collecting efficacy and effectiveness data and evaluating the immunogenicity and safety of the different formulations and adjuvants should lead to the identification of more ideal influenza vaccines that could be used with significant advantage in the entire pediatric population.

Original languageEnglish
Pages (from-to)7535-7541
Number of pages7
JournalVaccine
Volume29
Issue number43
DOIs
Publication statusPublished - Oct 6 2011

Fingerprint

Influenza Vaccines
childhood
influenza
Human Influenza
adjuvants
Vaccination
vaccination
vaccines
Pediatrics
Safety
Pandemics
Chronic Disease
pandemic
Population
immune response
death

Keywords

  • Adjuvants
  • Children
  • Influenza
  • Influenza vaccination
  • Prevention
  • Vaccine formulations

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Different influenza vaccine formulations and adjuvants for childhood influenza vaccination. / Esposito, Susanna; Principi, Nicola.

In: Vaccine, Vol. 29, No. 43, 06.10.2011, p. 7535-7541.

Research output: Contribution to journalArticle

Esposito, Susanna ; Principi, Nicola. / Different influenza vaccine formulations and adjuvants for childhood influenza vaccination. In: Vaccine. 2011 ; Vol. 29, No. 43. pp. 7535-7541.
@article{17501ae20afa4559b4070a711754055c,
title = "Different influenza vaccine formulations and adjuvants for childhood influenza vaccination",
abstract = "Pediatric influenza is a very common disease: attack rates range from 23{\%} to 48{\%} during interpandemic years and are significantly higher during pandemics. Influenza-related complications seem to be more common in children at risk because of an underlying chronic severe disease, but recently collected data clearly demonstrate that otherwise healthy children can also suffer from severe influenza and that the annual number of deaths is no different between the two groups. The aim of this review is to discuss the characteristics of all influenza vaccines in order to evaluate the real likelihood of prevention, as well as the safety and tolerability of the different formulations and adjuvants. The data indicate that further studies collecting efficacy and effectiveness data and evaluating the immunogenicity and safety of the different formulations and adjuvants should lead to the identification of more ideal influenza vaccines that could be used with significant advantage in the entire pediatric population.",
keywords = "Adjuvants, Children, Influenza, Influenza vaccination, Prevention, Vaccine formulations",
author = "Susanna Esposito and Nicola Principi",
year = "2011",
month = "10",
day = "6",
doi = "10.1016/j.vaccine.2011.08.012",
language = "English",
volume = "29",
pages = "7535--7541",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "43",

}

TY - JOUR

T1 - Different influenza vaccine formulations and adjuvants for childhood influenza vaccination

AU - Esposito, Susanna

AU - Principi, Nicola

PY - 2011/10/6

Y1 - 2011/10/6

N2 - Pediatric influenza is a very common disease: attack rates range from 23% to 48% during interpandemic years and are significantly higher during pandemics. Influenza-related complications seem to be more common in children at risk because of an underlying chronic severe disease, but recently collected data clearly demonstrate that otherwise healthy children can also suffer from severe influenza and that the annual number of deaths is no different between the two groups. The aim of this review is to discuss the characteristics of all influenza vaccines in order to evaluate the real likelihood of prevention, as well as the safety and tolerability of the different formulations and adjuvants. The data indicate that further studies collecting efficacy and effectiveness data and evaluating the immunogenicity and safety of the different formulations and adjuvants should lead to the identification of more ideal influenza vaccines that could be used with significant advantage in the entire pediatric population.

AB - Pediatric influenza is a very common disease: attack rates range from 23% to 48% during interpandemic years and are significantly higher during pandemics. Influenza-related complications seem to be more common in children at risk because of an underlying chronic severe disease, but recently collected data clearly demonstrate that otherwise healthy children can also suffer from severe influenza and that the annual number of deaths is no different between the two groups. The aim of this review is to discuss the characteristics of all influenza vaccines in order to evaluate the real likelihood of prevention, as well as the safety and tolerability of the different formulations and adjuvants. The data indicate that further studies collecting efficacy and effectiveness data and evaluating the immunogenicity and safety of the different formulations and adjuvants should lead to the identification of more ideal influenza vaccines that could be used with significant advantage in the entire pediatric population.

KW - Adjuvants

KW - Children

KW - Influenza

KW - Influenza vaccination

KW - Prevention

KW - Vaccine formulations

UR - http://www.scopus.com/inward/record.url?scp=80053443019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053443019&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.08.012

DO - 10.1016/j.vaccine.2011.08.012

M3 - Article

C2 - 21820478

AN - SCOPUS:80053443019

VL - 29

SP - 7535

EP - 7541

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 43

ER -